Athens Medical C.S.A. (IATR)
Athens Exchange · Greece · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 1.470 |
|---|---|
| 52-week range | 1.370 – 2.190 |
| Return, 1 month / 3 months | −3.9% / −7.0% |
| Return, 1 year / 3 years | −21.2% / −12.5% |
| Trend | Below its 200-day average |
| RSI (14) | 48 |
| Volatility (1 year) | 29.5% |
| Worst drawdown (1 year) | -32.0% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Athens Medical C.S.A. runs private hospitals and diagnostic centres, providing medical care and related health services to patients in Greece and abroad. Its facilities offer inpatient and outpatient treatment across a range of specialties, along with laboratory testing and imaging. The group is headquartered in Athens and serves individuals, private patients and insurance arrangements through its network of clinics and medical units.
On this site Athens Medical C.S.A. appears as a stock on the Athens Exchange (Greece), code IATR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Athens Medical C.S.A. (IATR) trades on the Athens Exchange in Greece. It last closed at EUR 1.470 on 22 October 2026.
Its price-based Market X-Ray is 25 out of 100 (a weak price profile), ranking 123 of 143 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.2% and over the last three months it fell 7.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Athens Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 16 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.9% | ||
| From 52-week high | -28.6% | ||
| Momentum | 17 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -7.0% | ||
| 6-month return | -25.6% | ||
| 12-month return, skipping the last month | -18.0% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.0% | ||
| Liquidity | 25 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.0% |
|---|---|
| 1 month | −3.9% |
| 3 months | −7.0% |
| 6 months | −25.6% |
| 1 year | −21.2% |
| 3 years | −12.5% |
| 5 years | −12.7% |
Signals
| 50-day / 200-day average | 1.528 / 1.728 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.024 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Aug 2022 | EUR 0.0700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Athens Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.